in

Gland Pharma’s Hyderabad Facility Receives Establishment Inspection Report From USFDA

Gland Pharma’s profit dipped to Rs 163.53 crore, representing a 16% fall, for the quarter ended Sept. 30, 2024, of the fiscal 2025 as compared to Rs 194.08 crore for the same period last year.

The pharma major’s revenue rose by 2.4% to Rs 1,405.83 crore for the second quarter as against Rs…

Read More

What do you think?

Written by pulseadmin

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Infosys slips 6% post Q3 results, drags down Nifty IT index

Vietnam’s VinFast To Roll Out Two Cars In 2025 In India Debut